A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

Blackwell Publishing

Access to resources Recommend Favorite

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

By Hollebecque A.   Deutsch E.   Massard C.   Gomez-Roca C.   Bahleda R.   Ribrag V.   Bourgier C.   Lazar V.   Lacroix L.   Gazzah A.   Varga A.   Baere T.   Beier F.   Kroesser S.   Trang K.   Zenke F.   Klevesath M.   Soria Jean-Charles  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1530-1538

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors

By Camacho Luis   Olson Jon   Tong William   Young Charles   Spriggs David   Malkin Mark  

Investigational New Drugs, Vol. 25, Iss. 2, 2007-04 ,pp. : 131-138

Springer Publishing Company

Access to resources Recommend Favorite

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

By Blais Normand   Camidge D.   Jonker Derek   Soulières Denis   Laurie Scott   Diab Sami   Ruiz-Garcia Ana   Thall Aron   Zhang Ke   Chao Richard   Chow Laura  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1487-1498

Springer Publishing Company

Access to resources Recommend Favorite

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

By Samol Jens  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1493-1500

Springer Publishing Company

Access to resources Recommend Favorite